MAP4K3 regulation of cellular stress response pathways in health and disease

MAP4K3 对健康和疾病中细胞应激反应途径的调节

基本信息

  • 批准号:
    10530025
  • 负责人:
  • 金额:
    $ 202.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-12-01 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

Regulation of cellular metabolic status is determined by the mTORC1 complex, which senses systemic nutrient levels and intracellular nutrients. We set out to define the signaling pathways controlling autophagy activation, and discovered that MAP4K3 phosphorylation of transcription factor EB (TFEB) dictates autophagy status in the cell, and documented that MAP4K3 autophagy regulation lies upstream of mTORC1 autophagy regulation. MAP4K3 activates mTORC1 when amino acids are plentiful, but the basis for this regulation is ill-defined. During the current funding cycle, we delineated the MAP4K3 – mTORC1 signaling pathway, linking MAP4K3 activation of mTORC1 to inhibition of AMP-activated protein kinase. Our findings reveal MAP4K3 inhibition of AMPK may occur via phosphorylation of Sirtuin-1 resulting in LKB1 inactivation. To understand the scope of MAP4K3 function, we completed an interactome and phosphoproteomics analysis, and implicated MAP4K3 in regulation of the GATOR1/2 complex, which controls mTORC1 localization to the lysosome, a prerequisite step for mTORC1 activation. We also determined that MAP4K3 can localize to the nucleus, and may participate in the DNA damage response. All these findings indicate that MAP4K3 is a central node for the regulation of cellular homeostasis, serving as a nexus for cross-talk between pathways of metabolism, cell stress, and cell survival. We have begun to examine the physiological relevance of MAP4K3 phosphoregulation by deriving lines of mice with phosphoresistant and phosphomimetic amino acid substitutions at the TFEB serine residue (S3) subject to MAP4K3 phosphorylation. As mTORC1 dysregulation is implicated in cancer and neurological disease, our results suggest that one appealing therapeutic strategy for diseases of altered mTOR signaling function would be to develop drugs to inhibit MAP4K3. To achieve this goal, we performed in silico screening for small molecules that interfere with MAP4K3 open pocket dimerization, and evaluated 13 compounds in a series of secondary and tertiary assays, identifying three promising hits. In this renewal project, we will define components of the MAP4K3 amino acid sensing dependent pathway of mTORC1 activation and delineate the molecular basis for MAP4K3 regulation of mTORC1 activation, focusing on Sirtuin- 1 phosphoregulation by MAP4K3 and the nature of MAP4K3 interaction with the GATOR1/2 complex. We propose to assess MAP4K3 regulation of autophagy and cell stress by carefully characterizing phenotypes and autophagy function in TFEB S3A and S3E mice, and determining if MAP4K3 is involved in modulating DNA damage responses. We will build on our MAP4K3 inhibitor translational drug discovery work by honing in on the most promising lead compounds through structure-activity relationship generation of a compound series, coupled with an independent in silico screen and kinase inhibitor potency testing followed by a critical path of validation assays, and we will test if our lead MAP4K3 inhibitor(s) can rescue disease phenotypes in a mouse model of tuberous sclerosis complex (TSC) and in frontotemporal dementia / tauopathy Tsc1 +/- mice .
细胞代谢状态的调节是由mTORC1复合物决定的,它感知全身营养

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALBERT R LA SPADA其他文献

ALBERT R LA SPADA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALBERT R LA SPADA', 18)}}的其他基金

Molecular genetic regulation of autophagy in health and neurodegenerative disease
健康和神经退行性疾病中自噬的分子遗传调控
  • 批准号:
    10367877
  • 财政年份:
    2022
  • 资助金额:
    $ 202.26万
  • 项目类别:
La Spada Outstanding Investigator Award
拉斯帕达杰出研究者奖
  • 批准号:
    10227293
  • 财政年份:
    2021
  • 资助金额:
    $ 202.26万
  • 项目类别:
La Spada Outstanding Investigator Award
拉斯帕达杰出研究者奖
  • 批准号:
    10401437
  • 财政年份:
    2021
  • 资助金额:
    $ 202.26万
  • 项目类别:
La Spada Outstanding Investigator Award
拉斯帕达杰出研究者奖
  • 批准号:
    10618880
  • 财政年份:
    2021
  • 资助金额:
    $ 202.26万
  • 项目类别:
La Spada Outstanding Investigator Award
拉斯帕达杰出研究者奖
  • 批准号:
    10652719
  • 财政年份:
    2021
  • 资助金额:
    $ 202.26万
  • 项目类别:
Ataxia Investigators Meeting 8: Leveraging Therapeutic Opportunity into Novel Treatment Paradigms
共济失调研究者会议 8:利用治疗机会开发新型治疗范式
  • 批准号:
    9913421
  • 财政年份:
    2020
  • 资助金额:
    $ 202.26万
  • 项目类别:
Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy
解构 SBMA 运动神经元疾病的细胞和分子基础:从机制到治疗
  • 批准号:
    10355757
  • 财政年份:
    2016
  • 资助金额:
    $ 202.26万
  • 项目类别:
Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy
解构 SBMA 运动神经元疾病的细胞和分子基础:从机制到治疗
  • 批准号:
    9535519
  • 财政年份:
    2016
  • 资助金额:
    $ 202.26万
  • 项目类别:
Ataxin-7 oligonucleotide knock-down to treat SCA7 retinal and cerebellar disease
Ataxin-7 寡核苷酸敲低治疗 SCA7 视网膜和小脑疾病
  • 批准号:
    8774128
  • 财政年份:
    2014
  • 资助金额:
    $ 202.26万
  • 项目类别:
Ataxin-7 oligonucleotide knock-down to treat SCA7 retinal and cerebellar disease
Ataxin-7 寡核苷酸敲低治疗 SCA7 视网膜和小脑疾病
  • 批准号:
    9321472
  • 财政年份:
    2014
  • 资助金额:
    $ 202.26万
  • 项目类别:

相似海外基金

Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
  • 批准号:
    2867610
  • 财政年份:
    2023
  • 资助金额:
    $ 202.26万
  • 项目类别:
    Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
  • 批准号:
    BB/W009633/1
  • 财政年份:
    2022
  • 资助金额:
    $ 202.26万
  • 项目类别:
    Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2021
  • 资助金额:
    $ 202.26万
  • 项目类别:
    Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
  • 批准号:
    459043
  • 财政年份:
    2021
  • 资助金额:
    $ 202.26万
  • 项目类别:
    Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2020
  • 资助金额:
    $ 202.26万
  • 项目类别:
    Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10561642
  • 财政年份:
    2019
  • 资助金额:
    $ 202.26万
  • 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2019
  • 资助金额:
    $ 202.26万
  • 项目类别:
    Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
  • 批准号:
    2243045
  • 财政年份:
    2019
  • 资助金额:
    $ 202.26万
  • 项目类别:
    Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10359032
  • 财政年份:
    2019
  • 资助金额:
    $ 202.26万
  • 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
  • 批准号:
    428988
  • 财政年份:
    2019
  • 资助金额:
    $ 202.26万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了